BCL6 and B-cell non-Hodgkin lymphoma: The prognostic implications of DHL and THL underlie the 2017 World Health Organization (WHO) update, which includes the cytogenetically defined category of “High grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements” (DHL/THL) as its own distinct entity3.